Neo Ivy Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Neo Ivy Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$777K	Buy	+7,068	New	+$458K	0.53%	49

Other funds holding RXDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Neo Ivy Capital Management's RXDX Position: Q4 2022 in Review

Neo Ivy Capital Management opened a new position in Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2022: 7,068 shares worth $777K. The stake represents 0.53% of the portfolio and ranks #49 among its holdings.

221 funds tracked by Wall St. Rank hold RXDX as of Q4 2022.

Neo Ivy Capital Management held 7,068 shares of Prometheus Biosciences, Inc. Common Stock worth $777K as of Q4 2022.
Prometheus Biosciences, Inc. Common Stock was a new Neo Ivy Capital Management position in Q4 2022.
Prometheus Biosciences, Inc. Common Stock made up 0.53% of Neo Ivy Capital Management's portfolio in Q4 2022, its #49 holding.
221 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2022.

Based on Neo Ivy Capital Management's 13F filing for Q4 2022, filed 27 Mar 2023.